HALOZYME THERAPEUTICS, INC. — Form 8-K
Filed September 22, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Halozyme issued $1,500,000,000 aggregate principal amount of 1.50% Convertible Senior Notes due October 1, 2033, dated September 22, 2026. Initial conversion rate: 7.1509 shares per $1,000 principal. Notes convertible under specific conditions including stock price >130% of conversion price, trading price <98% of stock price × conversion rate, or specified corporate events. Company may redeem notes on/after October 7, 2030 if stock price exceeds 130% of conversion price for ≥20 of 30 trading days.
Why this rating
Large financing (~$1.5B, 33% of $4.5B market cap) provides capital but is routine convertible issuance with standard terms; minimal immediate business impact.
See more from September 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.